AstronauTx closes £48 million ($61 million) Series A financing to create new treatments for Alzheimer’s disease

  • AstronauTx is a biotech company developing new treatments for neurodegenerative conditions based on amplifying the brain’s own physiological protective mechanisms
  • Proceeds of the financing will be used to advance a portfolio of programmes and take the lead molecule into clinical trials
  • The syndicate, led by the Novartis Venture Fund, also includes MPM Capital, Brandon Capital, EQT Life Sciences, Bristol Myers Squibb and current insider the Dementia Discovery Fund

Read more…